Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium

被引：25

作者：

Sola, Elsa ^{[1
,2
,3
]}

Pose, Elisa ^{[1
,2
,3
]}

Campion, Daniela ^{[4
]}

Piano, Salvatore ^{[5
]}

Roux, Olivier ^{[6
]}

Simon-Talero, Macarena ^{[7
]}

Uschner, Frank ^{[8
]}

de Wit, Koos ^{[9
]}

Zaccherini, Giacomo ^{[10
]}

Alessandria, Carlo ^{[4
]}

Beuers, Ulrich ^{[9
]}

Caraceni, Paolo ^{[10
]}

Francoz, Claire ^{[6
]}

Mookerjee, Rajeshwar P. ^{[11
]}

Trebicka, Jonel ^{[8
]}

Vargas, Victor ^{[7
]}

Serra, Miquel ^{[12
]}

Torres, Ferran ^{[13
]}

Montagnese, Sara ^{[14
]}

Krag, Aleksander ^{[15
,16
,17
]}

Hernaez, Ruben ^{[18
,19
,20
]}

Korenjak, Marko ^{[21
]}

Watson, Hugh ^{[22
,23
]}

Abraldes, Juan G. ^{[24
]}

Kamath, Patrick S. ^{[25
]}

Gines, Pere ^{[1
,2
,3
]}

机构：

[1] Hosp Clin Barcelona, Liver Unit, Villarroel 170, Barcelona 08036, Spain

[2] Univ Barcelona, Sch Med & Hlth Sci, Barcelona, Spain

[3] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

[4] Univ Turin, Citta Salute & Sci Hosp, Div Gastroenterol & Hepatol, Turin, Italy

[5] Univ Padua, Dept Med DIMED, Unit Internal Med & Hepatol UIMH, Padua, Italy

[6] Hosp Beaujon, AP HP, Hepatol & Liver Intens Care Unit, Clichy, France

[7] Univ Autonoma Barcelona, Hosp Vall dHebron & Vall dHebron Res Unit VHIR, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Liver Unit, Barcelona, Spain

[8] Goethe Univ Frankfurt, Dept Internal Med 1, Frankfurt, Germany

[9] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands

[10] Alma Mater Studiorum Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[11] UCL, Inst Liver & Digest Hlth, London, England

[12] Univ Pompeu Fabra, Ctr Res Hlth & Econ, Barcelona, Catalonia, Spain

[13] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Biostat & Data Management Core Facil, Barcelona, Spain

[14] Univ Padua, Dept Med, Padua, Italy

[15] Odense Univ Hosp, Dept Gastroenterol & Hepatol, Odense, Denmark

[16] Odense Univ Hosp, Odense Patient Data Exploratory Network OPEN, Odense, Denmark

[17] Univ Southern Denmark, Inst Clin Res, Odense, Denmark

[18] Houston TX Ctr, Michael E DeBakey Vet Affairs Med Ctr, Sect Gastroenterol, Houston, TX USA

[19] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety IQuESt, Houston, TX USA

[20] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA

[21] European Liver Patients Assoc ELPA, Brussels, Belgium

[22] Evotec ID, Lyon, France

[23] Aarhus Univ, Dept Hepatol & Gastroenterol, Aarhus, Denmark

[24] Univ Alberta, Div Gastroenterol, CEGIIR, Cirrhosis Care Clin,Liver Unit, Edmonton, AB, Canada

[25] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA

来源：

JOURNAL OF HEPATOLOGY | 2021年 / 74卷 / 01期

关键词：

Cirrhosis; Liver transplant; Clinical trials; Endpoints; Ascites; AKI; Hepatic encephalopathy; Hyponatremia; Infections; ACLF; Quality of life; QUALITY-OF-LIFE; SPONTANEOUS BACTERIAL PERITONITIS; V-2 RECEPTOR ANTAGONIST; LONG-TERM PROGNOSIS; INTRAHEPATIC PORTOSYSTEMIC SHUNTS; GELATINASE-ASSOCIATED LIPOCALIN; SERUM SODIUM CONCENTRATION; PARACENTESIS PLUS ALBUMIN; URINARY ETHYL GLUCURONIDE; ACUTE KIDNEY INJURY;

D O I：

10.1016/j.jhep.2020.08.009

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Management of decompensated cirrhosis is currently geared towards the treatment of complications once they occur. To date there is no established disease-modifying therapy aimed at halting progression of the disease and preventing the development of complications in patients with decompensated cirrhosis. The design of clinical trials to investigate new therapies for patients with decompensated cirrhosis is complex. The population of patients with decompensated cirrhosis is heterogeneous (i.e., different etiologies, comorbidities and disease severity), leading to the inclusion of diverse populations in clinical trials. In addition, primary endpoints selected for trials that include patients with decompensated cirrhosis are not homogeneous and at times may not be appropriate. This leads to difficulties in comparing results obtained from different trials. Against this background, the LiverHope Consortium organized a meeting of experts, the goal of which was to develop recommendations for the design of clinical trials and to define appropriate endpoints, both for trials aimed at modifying the natural history and preventing progression of decompensated cirrhosis, as well as for trials aimed at managing the individual complications of cirrhosis. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V.

引用

页码：200 / 219

页数：20

共 50 条

[21] Relative Adrenal Insufficiency is Associated with the Clinical Outcome in Patients with Stable Decompensated Cirrhosis
Cholongitas, Evangelos
Goulis, Ioannis
Pagkalidou, Eirini
Haidich, Anna B.
Karagiannis, Apostolos K. A.
Nakouti, Theodora
Pipili, Chrysoula
Oikonomou, Theodora
Gerou, Spyros
Akriviadis, Evangelos
ANNALS OF HEPATOLOGY, 2017, 16 (04) : 584 - 590
[22] A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients
Shah, Neeral L.
Northup, Patrick G.
Caldwell, Stephen H.
ANNALS OF HEPATOLOGY, 2012, 11 (05) : 686 - 690
[23] Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper
Pfaar, O.
Demoly, P.
van Wijk, R. Gerth
Bonini, S.
Bousquet, J.
Canonica, G. W.
Durham, S. R.
Jacobsen, L.
Malling, H. J.
Moesges, R.
Papadopoulos, N. G.
Rak, S.
Rodriguez del Rio, P.
Valovirta, E.
Wahn, U.
Calderon, M. A.
ALLERGOLOGIE, 2015, 38 (11) : 545 - 566
[24] Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper
Pfaar, O.
Demoly, P.
van Wijk, R. Gerth
Bonini, S.
Bousquet, J.
Canonica, G. W.
Durham, S. R.
Jacobsen, L.
Malling, H. J.
Moesges, R.
Papadopoulos, N. G.
Rak, S.
Rodriguez del Rio, P.
Valovirta, E.
Wahn, U.
Calderon, M. A.
ALLERGY, 2014, 69 (07) : 854 - 867
[25] The role of the pathologist in the design and conducting of biomarker-driven clinical trials in cancer: position paper of the European Society of Pathology
Matias-Guiu, Xavier
Raspollini, Maria Rosaria
Kulka, Janina
Ryska, Ales
Dieri, Raed Al
Schirmacher, Peter
European Society of Pathology ESP
VIRCHOWS ARCHIV, 2024, : 207 - 214
[26] Selection of study endpoints and patients for clinical trials in primary Sjogren's syndrome
Arends, S.
de Wolff, L.
Deroo, L.
Verstappen, G. M.
Vissink, A.
Kroese, F. G. M.
Elewaut, D.
Peene, I.
Bootsma, H.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (12) : 2225 - 2232
[27] Natriuretic Peptides as Inclusion Criteria in Clinical Trials A JACC: Heart Failure Position Paper
Ibrahim, Nasrien E.
Burnett, John C., Jr.
Butler, Javed
Camacho, Alexander
Felker, G. Michael
Fiuzat, Mona
O'Connor, Christopher
Solomon, Scott D.
Vaduganathan, Muthiah
Zile, Michael R.
Januzzi, James L.
JACC-HEART FAILURE, 2020, 8 (05) : 347 - 358
[28] Study Design Characteristics and Endpoints for Enriched Enrollment Randomized Withdrawal Trials for Chronic Pain Patients: A Systematic Review
Kopsky, David J.
Szadek, Karolina M.
Schober, Patrick
Vrancken, Alexander F. J. E.
Steegers, Monique A. H.
JOURNAL OF PAIN RESEARCH, 2022, 15 : 479 - 496
[29] Clinical trials and patients' rights: the debate on the position of Veronesi Foundation
不详
ASSISTENZA INFERMIERISTICA E RICERCA, 2014, 33 (01) : 48 - 52
[30] Effects of renin-angiotensin inhibitors on renal function and the clinical course in patients with decompensated cirrhosis
Tergast, Tammo L.
Griemsmann, Marie
Wedemeyer, Heiner
Cornberg, Markus
Maasoumy, Benjamin
SCIENTIFIC REPORTS, 2023, 13 (01)

← 1 2 3 4 5 →